|
Adjuvant Prostate XRP6976J
|
SANOFI-AVENTIS
A Multicenter, Open Label, Randomized Phase III Trial Comparing Immediate Adjuvant Hormonal Therapy (Eligard-Leuprolide Acetate) in combination with Taxotere Administered every 3 weeks versus Hormonal Therapy along Versus Deferred Therapy Followed by the same Therapeutic Options in Patients with Prostate Cancer at High Risk of Relapse after Radical Prostatectomy
|
III |
Taxotere
Eligard
Leuprolide
|
|
Metastatic Prostate
D9902B
|
DENDREON
A Randomized, Double Blind, Placebo Controlled, Phase III Trial of Immunotherapy with Autologous Antigen Presenting Cells Loaded with PA2024 (Provenge, APC8015) in Men with Metastic Androgen Independent Prostatic Adenocarcinoma
|
III |
Provenge
APC8015
|
|
Metastatic Prostate
PB01
|
DENDREON
An Open Label, Single Arm Trial of Immunotherapy with Autologous Presenting Cells Loaded with PA2024 (APC8015) for Subjects with Objective Disease Progression and Disease Related Pain on D9902B
|
|
Provenge
APC8015F
|
|
Metastatic Prostate
CALGB 90401
|
CALGB
A Randomized Double Blinded Placebo Controlled Phase III Trial Comparing Docetaxel and Prednisone with and without Bevacizumab in Men with Hormone Refractory Prostate Cancer
|
III |
Docetaxel
Prednisone
Bevacizumab
|
|
Metastatic
Prostate
G0034
|
CELL GENESYS
A phase III Randomized, Open Label Study of Docetaxel in Combination with CG-1940 versus Docetaxel and Prednisone in Taxane Naïve Patients with Metastatic Hormone Refractory Prostate Cancer with Pain
|
III |
Docetaxel
Prednisone
CG-41104
|
|
Prostate
E5803
|
Phase II Trial of GW572016 in Patients with Recurrent Prostate Cancer as Evident by a Rising PSA
|
|
|
|
Prostate
AR140006
|
A Randomized Double-Blind, Placebo-Controlled, Parallel Group Study of the Efficacy and Safety of Dutasteride 0.5mg Administered Once Daily for Four Years to Reduce the Risk of Biopsy-Detectable Prostate Cancer
|
|
|
|
Prostate
S0000
|
Selenium and Vitamin E Cancer Prevention Trial (SELECT)
|
|
|
|
Prostate
S0437
|
Prostate Cancer Prevention Trial (PCPT) Companion Long Term Follow Up Study for Men Diagnosed with Prostate Cancer
|
|
|
|
Prostate
|
GUILFORD PHARMACEUTICALS
Phase II Multi-Center, Randomized, Double-blind, Placebo-Controlled, 3-Arm,12 month study to evaluate the effects of GPI 1485 on erectile function in patients undergoing bilateral nerve sparing radical retropubic prostatectomies for prostates carcinoma
|
|
|
|
Prostate
|
SANOFI-SYNTHELABO, INC.
Prospective, Observational Registry of the Management of Men with Prostate Cancer and a Rising PSA Following Definitive Surgical or Radiological Treatment of the Primary Tumor: PCA Registry COMPARE (Comprehensive, Observational, Multicenter Prostate Adenocarcinoma Registry)
|
|
|
|
Adjuvant Renal Cell Ca
C 100-12 PII
|
ANTIGENICS
A Multi Center, Randomized Phase III Study of Adjuvant Oncophage versus Observation in Patients with High Risk of Recurrence after Surgical Treatment of Renal Cell Carcinoma
|
III |
Oncophage
HSPPC – 96
|
|
Metastatic Renal Cell Ca
E8802
|
ECOG
Phase II Trial of Doxorubicin and Gemcitabine in Metastatic Renal Cell Carcinoma with Sarcomatoid Features
|
II |
Doxorubicin
Gemcitabine
|
|
Metastatic
Renal Cell Ca
BAY 11868
|
BAYER
Open Label, Non-comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma
|
EAP |
Sorafenib
|
|
Metastatic Renal Cell Ca
CALGB 90206
|
CALGB
A Randomized Phase III Trial of Interferon alfa 2B or Interferon Alfa 2B plus Bevacizumab in Patients with Advanced Renal Cell Carcinoma
|
III |
Interferon Alfa
Bevacizumab
|
Renal Cell Carcinoma
E2805 |
A Randomized, Double-Blind Phase III Trial of Adjuvant Sunitinib versus Sorafenib versus Placebo in Patients with Resected Renal Cell Carcinoma
A Phase II Study of Sorafenib in Patients with Metastatic Renal Cell Carcinoma
Phase II Study of Interleukin-2 and Bevacizumab in Patients with Progressive Metastatic Renal Cell Carcinoma
|
|
|
|
Urothelial Carcinoma
E-1804
|
Phase II Trial of Sorafenib (BAY43-9006) (IND 69896; NSC 724772) in Patients with Advanced Urothelial Cancer
|
|
|
|
Bladder
|
PHOTOCURE ASA
A Randomized, Comparative, Controlled Phase III, Multi-Center Study of Hexvix Flourescence Cystoscopy and White Light Cystoscopy in the Detection of Papillary Bladder Cancer and the Early Recurrence Rate in Patients with Bladder Cancer
|
|
|